These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 19221040)

  • 21. SHIP limits immunoregulatory capacity in the T-cell compartment.
    Collazo MM; Wood D; Paraiso KH; Lund E; Engelman RW; Le CT; Stauch D; Kotsch K; Kerr WG
    Blood; 2009 Mar; 113(13):2934-44. PubMed ID: 19136659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
    Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells.
    Lan F; Zeng D; Higuchi M; Huie P; Higgins JP; Strober S
    J Immunol; 2001 Aug; 167(4):2087-96. PubMed ID: 11489992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants.
    Hongo D; Tang X; Dutt S; Nador RG; Strober S
    Blood; 2012 Feb; 119(6):1581-9. PubMed ID: 22174155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
    Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
    J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease.
    Yang J; Ramadan A; Reichenbach DK; Loschi M; Zhang J; Griesenauer B; Liu H; Hippen KL; Blazar BR; Paczesny S
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30694220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
    Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
    Front Immunol; 2018; 9():3104. PubMed ID: 30733722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease.
    Nishikii H; Kim BS; Yokoyama Y; Chen Y; Baker J; Pierini A; Alvarez M; Mavers M; Maas-Bauer K; Pan Y; Chiba S; Negrin RS
    Blood; 2016 Dec; 128(24):2846-2858. PubMed ID: 27760760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donor bone marrow cells are essential for iNKT cell-mediated Foxp3+ Treg cell expansion in a murine model of transplantation tolerance.
    Miyairi S; Hirai T; Ishii R; Okumi M; Nunoda S; Yamazaki K; Ishii Y; Tanabe K
    Eur J Immunol; 2017 Apr; 47(4):734-742. PubMed ID: 28127757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
    Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
    Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
    Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
    Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease.
    Tawara I; Shlomchik WD; Jones A; Zou W; Nieves E; Liu C; Toubai T; Duran-Struuck R; Sun Y; Clouthier SG; Evers R; Lowler KP; Levy RB; Reddy P
    J Immunol; 2010 Oct; 185(7):3866-72. PubMed ID: 20810991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Host CD25+CD4+Foxp3+ regulatory T cells primed by anti-CD137 mAbs inhibit graft-versus-host disease.
    Kim J; Kim W; Kim HJ; Park S; Kim HA; Jung D; Choi HJ; Park SJ; Mittler RS; Cho HR; Kwon B
    Biol Blood Marrow Transplant; 2012 Jan; 18(1):44-54. PubMed ID: 21958951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality.
    Schneidawind D; Baker J; Pierini A; Buechele C; Luong RH; Meyer EH; Negrin RS
    Blood; 2015 May; 125(22):3491-500. PubMed ID: 25795920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
    Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
    Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of acute graft-versus-host disease and chimerism after adoptive transfer of in vitro-expanded invariant Valpha14 natural killer T cells.
    Kuwatani M; Ikarashi Y; Iizuka A; Kawakami C; Quinn G; Heike Y; Yoshida M; Asaka M; Takaue Y; Wakasugi H
    Immunol Lett; 2006 Jul; 106(1):82-90. PubMed ID: 16806496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
    Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
    J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
    Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
    Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.
    Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN
    J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.